PAION AG - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 42
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: PA5FB80A2F2EN
Leaflet:

Download PDF Leaflet

PAION AG - Product Pipeline Review - Q4 2010
PAION AG – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “PAION AG – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • PAION AG – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of PAION AG human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of PAION AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the PAION AG’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate PAION AG’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of PAION AG in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the PAION AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with PAION AG.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of PAION AG and identify potential opportunities in those areas.
PAION AG Snapshot
PAION AG Overview
Key Information
Key Facts
PAION AG – Research and Development Overview
Key Therapeutic Areas
PAION AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
PAION AG – Pipeline Products Glance
PAION AG – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
PAION AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
PAION AG – Drug Profiles
Morphine-6-glucuronide
  Product Description
  Mechanism of Action
  R&D Progress
CNS 7056
  Product Description
  Mechanism of Action
  R&D Progress
Flovagatran
  Product Description
  Mechanism of Action
  R&D Progress
Solulin
  Product Description
  Mechanism of Action
  R&D Progress
PAION AG – Pipeline Analysis
PAION AG – Pipeline Products by Therapeutic Class
PAION AG Pipeline Products By Target
PAION AG – Pipeline Products by Route of Administration
PAION AG – Pipeline Products by Molecule Type
PAION AG – Recent Pipeline Updates
PAION AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CNS 5161
PAION AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Feb 04, 2010: PAION ANNOUNCES INITIATION OF CLINICAL DEVELOPMENT ACTIVITIES WITH SHORT-ACTING ANAESTHETIC/SEDATIVE CNS 7056 (ONO’S DEVELOPMENT CODE: ONO-2745) BY ITS PARTNER ONO PHARMACEUTICAL IN JAPAN
Oct 05, 2009: ABSTRACT ON CNS 7056 HAS BEEN CHOSEN AS ONE OF THE BEST ABSTRACTS BY THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS (ASA)
Apr 09, 2009: Paion And Ergomed Reports Full Data Of CNS 5161 Phase IIa Study In Neuropathic Cancer Pain
Jan 09, 2009: PAION’S NOVEL SEDATIVE/ANAESTHETIC CNS 7056 MEETS TARGET PROFILE IN HUMAN PROOF OF CONCEPT STUDY
Nov 03, 2008: Paion Sees Improved Probability Of Success For Pain Drug M6G Following Successful Meta-Analysis Of Clinical Data
May 21, 2008: Paion’s Anticoagulant Solulin Achieves Proof Of Concept For Mode Of Action In Phase I
May 21, 2008: Paion’s Anticoagulant Solulin Achieves Proof Of Concept For Mode Of Action In Phase I
Feb 28, 2008: Paion’s Anticoagulant Solulin Successfully Testes In First-In-Man Study
Feb 28, 2008: Paion’s Anticoagulant Solulin Successfully Testes In First-In-Man Study
Oct 24, 2007: Paion Reports Successful Start Of Phase I Study With Anticoagulant Solulin
Financial Deals Landscape
PAION AG, Deals Volume Summary, 2004 to YTD 2010
PAION AG, Deals Summary By Region, 2004 to YTD 2010
PAION AG, Deals Summary, 2004 to YTD 2010
PAION AG Detailed Deal Summary
Venture Financing
PAION Secures $12 Million In Venture Financing Round
Lundbeck Enters Into Agreement With PAION
Forest Laboratories Enters Into An Agreement With PAION
PAION Terminates Co-development Agreement With Forest Laboratories
Licensing Agreements
Lundbeck Expands License Agreement With PAION
PAION Entered Into Licensing Agreement With Nippon Shinyaku
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 42

LIST OF TABLES

PAION AG – Pipeline by Therapy Area and Indication, 2010
PAION AG – Pipeline by Stage of Development, 2010
PAION AG – Monotherapy Products in Pipeline, 2010
PAION AG – Phase III, 2010
PAION AG - Phase II, 2010
PAION AG - Phase I, 2010
PAION AG - Pipeline By Therapeutic Class, 2010
PAION AG - Pipeline By Target, 2010
PAION AG – Pipeline By Route of Administration, 2010
PAION AG – Pipeline By Molecule Type, 2010
PAION AG – Recent Pipeline Updates, 2010
PAION AG - Discontinued Pipeline Products, 2010
PAION AG, Subsidiaries
PAION AG, Deals Summary, 2004 to YTD 2010
PAION AG, Deals Summary by Region, 2004 to YTD 2010
PAION AG, Deals Summary, 2004 to YTD 2010
PAION Secures $12 Million In Venture Financing Round
Lundbeck Enters Into Agreement With PAION
Forest Laboratories Enters Into An Agreement With PAION
PAION Terminates Co-development Agreement With Forest Laboratories
Lundbeck Expands License Agreement With PAION
PAION Entered Into Licensing Agreement With Nippon Shinyaku 40

LIST OF FIGURES

PAION AG – Pipeline by Therapy Area and Indication, 2010
PAION AG – Pipeline by Stage of Development, 2010
PAION AG – Monotherapy Products in Pipeline, 2010
PAION AG – Pipeline By Therapeutic Class, 2010
PAION AG - Pipeline By Target, 2010
PAION AG – Pipeline By Molecule Type, 2010 20

Ask Your Question

PAION AG - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: